Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP24A1 | Q07973 | 6/20 | 0.50 |
| ▸ | CYP26A1 | O43174 | 4/20 | 0.50 |
| ▸ | CYP27A1 | Q02318 | 3/20 | 0.50 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.47 |
| ▸ | THRA | P10827 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4096787 | 1.00 | CYP24A1 (0.50) | CYP24A1CYP26A1CYP27A1DGAT1CYP19A1 | |
| SCHEMBL14061633 | 0.91 | CYP24A1 (0.60) | CYP24A1CYP26A1CYP27A1CYP19A1THRA | |
| SCHEMBL14061860 | 0.88 | DGAT1 (0.50) | CYP24A1CYP26A1CYP27A1DGAT1THRA | |
| SCHEMBL4101945 | 0.86 | DGAT1 (0.64) | CYP24A1CYP26A1CYP27A1DGAT1CYP19A1 | |
| SCHEMBL13774777 | 0.86 | DGAT1 (0.64) | CYP24A1CYP26A1CYP27A1DGAT1CYP19A1 | |
| SCHEMBL14062006 | 0.84 | DGAT1 (0.47) | CYP26A1DGAT1CYP11B1CYP11B2 | |
| SCHEMBL17195438 | 0.83 | CYP24A1 (0.46) | CYP24A1CYP26A1CYP27A1DGAT1CYP19A1 | |
| SCHEMBL7798239 | 0.82 | CYP26A1 (0.57) | CYP24A1CYP26A1CYP27A1DGAT1CYP19A1 | |
| SCHEMBL10754664 | 0.81 | CYP26A1 (0.49) | CYP24A1CYP26A1CYP27A1DGAT1CYP19A1 | |
| SCHEMBL9855296 | 0.80 | CYP24A1 (0.63) | CYP24A1CYP26A1CYP27A1CYP19A1THRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090186900-A1 | COMPOUND | STERIX LIMITED (GB) | 2009-07-23 | — | — | US | disclosed |
| US-20090186900-A1 | COMPOUND | STERIX LIMITED (GB) | 2009-07-23 | — | — | US | disclosed |
| WO-2007096647-A2 | DIARYL COMPOUNDS AS NON-STEROIDAL INHIBITORS OF 17-BETA HYDROXYSTEROID DEHYDROGENASE AND/OR STEROID SULPHATASE FOR THE TREATMENT OF OESTROGEN-RELATED DISEASES SUCH AS HORMONE DEPENDENT BREAST CANCER | STERIX LIMITED (GB) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186900-A1 | COMPOUND | HSD17B2, HSD17B11, CYP17A1 | CYP24A1 50/4885CYP26A1 37/4885CYP27A1 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.